Marker Therapeutics (MRKR) said Monday it has been awarded a $2 million grant from the National Institutes of Health's Small Business Innovation Research program for the clinical investigation of MT-601 in patients with non-Hodgkin's lymphoma whose disease returned following treatment with anti-CD19 CAR T cell therapy.
The grant will support its phase 1 Apollo study of MT-601, which will enroll up to about 30 participants in the dose escalation phase of the trial, the company said. Including the latest grant, it has secured over $19 million in non-dilutive funding proceeds.
Price: 3.95, Change: +0.14, Percent Change: +3.67
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments